1.
Reipert BM, Ahmad RU, Turecek PL, Schwarz HP: Characterization of antibodies induced by human factor VIII in a murine knockout model of hemophilia A. Thromb Haemost 2000;84:826–832.
2.
Sadler JE: Biochemistry and genetics of von Willebrand factor. Annu Rev Biochem 1998;67:395–424.
3.
Goudemand J, Rothschild C, Demiguel V, Vinciguerrat C, Lambert T, Chambost H, Borel-Derlon A, Claeyssens S, Laurian Y, Calvez T: Influence of the type of factor VIII concentrate on the incidence of factor VIII inhibitors in previously untreated patients with severe hemophilia A. Blood 2006;107:46–51.
4.
Kallas A, Kuuse S, Maimets T, Pooga M: Von Willebrand factor and transforming growth factor-beta modulate immune response against coagulation factor VIII in FVIII-deficient mice. Thromb Res 2007;120:911–919.
5.
Behrmann M, Pasi J, Saint-Remy JM, Kotitschke R, Kloft M: Von Willebrand factor modulates factor VIII immunogenicity: comparative study of different factor VIII concentrates in a haemophilia A mouse model. Thromb Haemost 2002;88:221–229.
6.
Delignat S, Dasgupta S, Andre S, Navarrete AM, Kaveri SV, Bayry J, Andre MH, Chtourou S, Tellier Z, Lacroix-Desmazes S: Comparison of the immunogenicity of different therapeutic preparations of human factor VIII in the murine model of hemophilia A. Haematologica 2007;92:1423–1426.
7.
Chitta MS, Duhe RJ, Kermode JC: Cloning of the cDNA for murine von Willebrand factor and identification of orthologous genes reveals the extent of conservation among diverse species. Platelets 2007;18:182–198.
8.
Tiemessen MM, Kunzmann S, Schmidt-Weber CB, Garssen J, Bruijnzeel-Koomen CA, Knol EF, van Hoffen E: Transforming growth factor-beta inhibits human antigen-specific CD4+ T cell proliferation without modulating the cytokine response. Int Immunol 2003;15:1495–1504.
9.
Tan FL, Ginsburg D: What a polyclonal antibody sees in von Willebrand factor. Thromb Res 2008;121:519–526. Doi: 10.1016/j.thromres.2007.05.015.
10.
Carmona E, Aznar JA, Jorquera JI, Villanueva MJ, Sanchez-Cuenca JM: Detection of two different anti-factor VIII/von Willebrand factor antibodies of the IgA class in a hemophilic patient with a polyclonal factor VIII inhibitor of the IgG class. Thromb Res 1991;63:73–84.
11.
Ghosh K, Shetty S, Jijina F, Mohanty D: Development of anti-VWF antibody in a patient with severe haemophilia A following the development of high-grade non-Hodgkin’s lymphoma. Clin Lab Haematol 2002;24:191–193.
12.
Batlle J, Loures E, Vila P, Hernandez MC, Mendez JA, Torea J, Rendal E, Couselo MJ, Filgueira A, Lopez Fernandez MF: Alloantibody from a patient with severe von Willebrand disease inhibits von Willebrand factor-FVIII interaction. Ann Hematol 1997;75:111–115.
13.
Lenting PJ, Westein E, Terraube V, Ribba AS, Huizinga EG, Meyer D, de Groot PG, Denis CV: An experimental model to study the in vivo survival of von Willebrand factor. Basic aspects and application to the R1205H mutation. J Biol Chem 2004;279:12102–12109.
14.
Ware J, Russell SR, Marchese P, Ruggeri ZM: Expression of human platelet glycoprotein Ib alpha in transgenic mice. J Biol Chem 1993;268:8376–8382.
© 2008 S. Karger AG, Basel
2008
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the...
© 2008 S. Karger AG, Basel
2008
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.